TWI744215B - 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途 - Google Patents

檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途 Download PDF

Info

Publication number
TWI744215B
TWI744215B TW103138244A TW103138244A TWI744215B TW I744215 B TWI744215 B TW I744215B TW 103138244 A TW103138244 A TW 103138244A TW 103138244 A TW103138244 A TW 103138244A TW I744215 B TWI744215 B TW I744215B
Authority
TW
Taiwan
Prior art keywords
ferric citrate
patient
iron
content
average
Prior art date
Application number
TW103138244A
Other languages
English (en)
Chinese (zh)
Other versions
TW201609088A (zh
Inventor
安立奎 波拉多蘇
榮恩 班瑟爾
詹姆士Ｆ 三世 奧利維羅
Original Assignee
美商凱克斯生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凱克斯生物製藥公司 filed Critical 美商凱克斯生物製藥公司
Publication of TW201609088A publication Critical patent/TW201609088A/zh
Application granted granted Critical
Publication of TWI744215B publication Critical patent/TWI744215B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW103138244A 2013-11-04 2014-11-04 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途 TWI744215B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899,866 2013-11-04

Publications (2)

Publication Number Publication Date
TW201609088A TW201609088A (zh) 2016-03-16
TWI744215B true TWI744215B (zh) 2021-11-01

Family

ID=53005244

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103138244A TWI744215B (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途
TW110136784A TW202203910A (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於製備治療慢性腎病患者之貧血的藥劑之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110136784A TW202203910A (zh) 2013-11-04 2014-11-04 檸檬酸鐵用於製備治療慢性腎病患者之貧血的藥劑之用途

Country Status (15)

Country Link
US (3) US20160256486A1 (https=)
EP (2) EP3747432A1 (https=)
JP (3) JP2016535780A (https=)
KR (1) KR102392441B1 (https=)
CN (1) CN105873583A (https=)
AU (1) AU2014341975A1 (https=)
BR (1) BR112016009901A8 (https=)
CA (1) CA2928200A1 (https=)
EA (1) EA201690926A1 (https=)
HK (1) HK1223031A1 (https=)
IL (1) IL245317A0 (https=)
MX (1) MX2016005734A (https=)
SG (1) SG11201603091QA (https=)
TW (2) TWI744215B (https=)
WO (1) WO2015066593A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011011541A1 (en) 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
MX2021004640A (es) 2018-10-29 2021-05-28 Pharmacosmos Holding As Tratamiento de la deficiencia de hierro con carboximaltosa ferrica.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4347022A1 (en) * 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (https=) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
CA2619591C (en) * 2005-08-18 2020-03-24 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
JP2009525277A (ja) * 2006-01-30 2009-07-09 グロボアジア エルエルシー 軟組織石灰化の回復、予防、遅延または安定化方法
WO2011011541A1 (en) * 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
TW201609088A (zh) 2016-03-16
US20250360167A1 (en) 2025-11-27
CA2928200A1 (en) 2015-05-07
EP3065734A4 (en) 2017-05-17
SG11201603091QA (en) 2016-05-30
HK1223031A1 (zh) 2017-07-21
WO2015066593A1 (en) 2015-05-07
EP3747432A1 (en) 2020-12-09
AU2014341975A1 (en) 2016-05-19
JP2021073230A (ja) 2021-05-13
JP2016535780A (ja) 2016-11-17
EA201690926A1 (ru) 2016-09-30
KR20160096597A (ko) 2016-08-16
US20160256486A1 (en) 2016-09-08
EP3065734A1 (en) 2016-09-14
CN105873583A (zh) 2016-08-17
JP2019206562A (ja) 2019-12-05
IL245317A0 (en) 2016-06-30
US20190307791A1 (en) 2019-10-10
KR102392441B1 (ko) 2022-05-02
MX2016005734A (es) 2016-11-08
BR112016009901A8 (pt) 2020-04-14
JP6828100B2 (ja) 2021-02-10
TW202203910A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
AU2018203205B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
TWI744215B (zh) 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途
TWI812580B (zh) 檸檬酸鐵用於治療缺鐵性貧血之用途
KR20160105499A (ko) 철 트리말톨의 복용량 양생법
CN108883085A (zh) 用铁化合物和柠檬酸盐化合物的组合物疗法
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients